AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16287769 — intervention group
Group type: COMPARATOR
Intervention: Usual care for amiodarone
Number of subjects: 400000
Study 12011520 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine ethanol (CE group)
Number of subjects: 62
Study 12011520 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone‐iodine (PI group)
Number of subjects: 62
Study 10216812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg single dose)
Number of subjects: 14
Study 10216812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg repeated doses three times a day for six days and 60 mg on the seventh day)
Number of subjects: 14
Study 7598923 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.5 mg with morphine
Number of subjects: 60
Study 7598923 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1 mg with morphine
Number of subjects: 60
Study 7598923 — intervention group
Group type: COMPARATOR
Intervention: Morphine (control group)
Number of subjects: 60
Study 2366571 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh plasma
Number of subjects: 40
Study 2366571 — intervention group
Group type: COMPARATOR
Intervention: Fresh packed cell fraction
Number of subjects: 40
Study 7352669 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam maleate, 10 mg (95% confidence limits: 9-12 mg)
Number of subjects: 60
Study 7352669 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam maleate
Number of subjects: 60
Study 7352669 — intervention group
Group type: COMPARATOR
Intervention: Sodium thiopental, 200 mg
Number of subjects: 60
Study 29806664 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 30
Study 29806664 — intervention group
Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 30
Study 29806664 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study 27692526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus 440 μg
Number of subjects: 347
Study 27692526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus 880 μg
Number of subjects: 347
Study 27692526 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal sirolimus 44 μg
Number of subjects: 347
Study 24771163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea group (n=35 patients, 69 eyes)
Number of subjects: 54
Study 24771163 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=19 patients, 38 eyes)
Number of subjects: 54
Study 24771163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 22468985 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal, nondrug therapy (motor stimulation, activities of daily living, cognitive stimulation) for 6 months, 2 hours, 6 days a week
Number of subjects: 139
Study 22468985 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 139
Study 20589927 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine
Number of subjects: 40
Study 20589927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18513418 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods for evaluating treatment effect from an RCT with a recurrent outcome
Number of subjects: 0
Study 18513418 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-Poisson model
Number of subjects: 0
Study 18513418 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent-increment model
Number of subjects: 0
Study 18513418 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional Cox model
Number of subjects: 0
Study 18513418 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal Cox model
Number of subjects: 0
Study 15869766 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset blind individuals (EB)
Number of subjects: 0
Study 15869766 — intervention group
Group type: COMPARATOR
Intervention: Sighted counterparts (SC)
Number of subjects: 0
Study 12869856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (50 mg/hr) for 48 hours after aminophylline infusion
Number of subjects: 18
Study 10500017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato oleoresin (70-75 mg lycopene)
Number of subjects: 15
Study 10500017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene beadlets (70-75 mg lycopene)
Number of subjects: 15
Study 10500017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10500017 — intervention group
Group type: COMPARATOR
Intervention: Tomato juice
Number of subjects: 15
Study 7570895 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 0
Study 7570895 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine
Number of subjects: 0
Study 7570895 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of edrophonium and 3,4-diaminopyridine
Number of subjects: 0
Study 1721516 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline prepared in hydroxyethylstarch solution (HS-HES, n = 15)
Number of subjects: 45
Study 1721516 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.5 solution (6% HES; n = 15)
Number of subjects: 45
Study 1721516 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 45
Study 6160172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed antigen challenge
Number of subjects: 9
Study 31775669 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg) plus pessary
Number of subjects: 936
Study 31775669 — intervention group
Group type: COMPARATOR
Intervention: Progesterone (200 mg) alone
Number of subjects: 936
Study 28280973 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalosis normoxia (ALN)
Number of subjects: 11
Study 28280973 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalosis hypoxia (ALH)
Number of subjects: 11
Study 28280973 — intervention group
Group type: COMPARATOR
Intervention: Placebo normoxia (PLN)
Number of subjects: 11
Study 28280973 — intervention group
Group type: COMPARATOR
Intervention: Placebo hypoxia (PLH)
Number of subjects: 11
Study 28280973 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise alkalosis
Number of subjects: 11
Study 25839715 — intervention group
Group type: EXPERIMENTAL
Intervention: TETRA 1.5 W/kg
Number of subjects: 30
Study 25839715 — intervention group
Group type: EXPERIMENTAL
Intervention: TETRA 6.0 W/kg
Number of subjects: 30
Study 25839715 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 30
Study 23377334 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene plus betamethasone dipropionate
Number of subjects: 1152
Study 23377334 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene-only
Number of subjects: 1152
Study 23377334 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-only
Number of subjects: 1152
Study 20838771 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 1323
Study 20838771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 1323
Study 18950837 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 300 mg daily for 24 months
Number of subjects: 46
Study 18950837 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 46
Study 18950837 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 46
Study 16714251 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT), given orally.
Number of subjects: 187
Study 16714251 — intervention group
Group type: COMPARATOR
Intervention: Control group (without HRT)
Number of subjects: 187
Study 16714251 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 187
Study 15607150 — intervention group
Group type: COMPARATOR
Intervention: HDRILBT alone (Group A)
Number of subjects: 60
Study 15607150 — intervention group
Group type: EXPERIMENTAL
Intervention: HDRILBT with additional EBRT (Group B)
Number of subjects: 60
Study 15607150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study 11725694 — intervention group
Group type: EXPERIMENTAL
Intervention: DION (300 mg androstenedione, 150 mg dehydroepiandrosterone, 540 mg saw palmetto, 300 mg indole‐3‐carbinol, 625 mg chrysin, and 750 mg Tribulus terrestris per day)
Number of subjects: 55
Study 11725694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11725694 — intervention group
Group type: EXPERIMENTAL
Intervention: DION
Number of subjects: 55
Study 9298774 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming (SW)
Number of subjects: 11
Study 7965657 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg ondansetron tablet
Number of subjects: 36
Study 7965657 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg ondansetron tablet after a standard meal
Number of subjects: 36
Study 7965657 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg ondansetron tablet with magnesium hydroxide/aluminum hydroxide antacid
Number of subjects: 36
Study 2442936 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 39
Study 2442936 — intervention group
Group type: COMPARATOR
Intervention: Etretinate
Number of subjects: 39
Study 31900603 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06342674 (1, 3, 8 mg/kg/q2w or 6 mg/kg/q1w)
Number of subjects: 0
Study 31900603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30641142 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 (100 mg)
Number of subjects: 0
Study 30641142 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 (200 mg and 400 mg)
Number of subjects: 0
Study 28606906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional strategy (aggressive side branch protection strategy: elective two-stent strategy or jailed balloon technique)
Number of subjects: 566
Study 28606906 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (provisional two-stent strategy or jailed wire technique)
Number of subjects: 566
Study 26216250 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 0
Study 26216250 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 0
Study 24064252 — intervention group
Group type: COMPARATOR
Intervention: DeltatracII(®)
Number of subjects: 24
Study 24064252 — intervention group
Group type: EXPERIMENTAL
Intervention: QuarkRMR(®) using canopy
Number of subjects: 24
Study 24064252 — intervention group
Group type: EXPERIMENTAL
Intervention: CCMexpress(®) using canopy
Number of subjects: 24
Study 24064252 — intervention group
Group type: EXPERIMENTAL
Intervention: CCMexpress(®) using face tent
Number of subjects: 24
Study 24064252 — intervention group
Group type: EXPERIMENTAL
Intervention: CCMexpress(®) using facemask
Number of subjects: 24
Study 22092730 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity artificial daylight (0.5 mW/cm² - 3.7 mW/cm²)
Number of subjects: 20
Study 22092730 — intervention group
Group type: COMPARATOR
Intervention: Conventional LED-PDT
Number of subjects: 20
Study 22092730 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity artificial daylight
Number of subjects: 20
Study 18045737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold saline solution (4 degrees C, 39.2 degrees F)
Number of subjects: 16
Study 18045737 — intervention group
Group type: COMPARATOR
Intervention: Room temperature saline solution (23 degrees C, 73.4 degrees F)
Number of subjects: 16
Study 16428185 — intervention group
Group type: EXPERIMENTAL
Intervention: True interferences in subjects with a history of TMD
Number of subjects: 0
Study 16428185 — intervention group
Group type: COMPARATOR
Intervention: Placebo interferences in subjects without a history of TMD
Number of subjects: 0
Study 15332212 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (25 mg/kg/d intravenously or 35 mg/kg/d orally)
Number of subjects: 338
Study 15332212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 11359591 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 63
Study 11359591 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus Bupivacaine
Number of subjects: 63
Study 11359591 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 63
Study 9253964 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide hydrochloride 2%
Number of subjects: 20
Study 9253964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8491238 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg oral dose) during pregnancy
Number of subjects: 8
Study 8491238 — intervention group
Group type: COMPARATOR
Intervention: Postpartum (3-5 months after delivery)
Number of subjects: 8
Study 3545842 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 2000 IU kg‐1 h‐1 for 24 hours + heparin
Number of subjects: 129
Study 3545842 — intervention group
Group type: COMPARATOR
Intervention: Urokinase 4400 IU kg‐1 h‐1 for 12 hours + heparin
Number of subjects: 129
Study 31489742 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo stent (n = 124)
Number of subjects: 183
Study 31489742 — intervention group
Group type: COMPARATOR
Intervention: Taxus Liberté (n = 59)
Number of subjects: 183
Study 29303790 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min standardized relaxation break before debriefing
Number of subjects: 149
Study 29303790 — intervention group
Group type: COMPARATOR
Intervention: No relaxation break before debriefing (Control)
Number of subjects: 149
Study 27236001 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Systems AS01B
Number of subjects: 0
Study 27236001 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Systems AS01E
Number of subjects: 0
Study 27236001 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Systems AS03A
Number of subjects: 0
Study 27236001 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Systems AS04
Number of subjects: 0
Study 27236001 — intervention group
Group type: COMPARATOR
Intervention: Alum
Number of subjects: 0
Study 24916058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1464
Study 24916058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100-250 mg twice daily)
Number of subjects: 1464
Study 24916058 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl CR
Number of subjects: 1464
Study 22398174 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified package (gravity and maternal effort)
Number of subjects: 24847
Study 22398174 — intervention group
Group type: COMPARATOR
Intervention: Full package (controlled cord traction)
Number of subjects: 24847
Study 20088723 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned vaginal birth (VBAC)
Number of subjects: 298
Study 20088723 — intervention group
Group type: COMPARATOR
Intervention: Planned cesarean section (CS)
Number of subjects: 298
Study 20088723 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who changed from planned CS to VBAC
Number of subjects: 298
Study 18030175 — intervention group
Group type: COMPARATOR
Intervention: estradiol valerate (2 mg daily)
Number of subjects: 31
Study 18030175 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol valerate in combination with testosterone undecanoate (40 mg every 2 days)
Number of subjects: 31
Study 16161915 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 72
Study 16161915 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 72
Study 16161915 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 72
Study 14522025 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatography (HPLC) method for cyclosporine determination
Number of subjects: 0
Study 11157569 — intervention group
Group type: EXPERIMENTAL
Intervention: 1H‐MRSI in patients with MCD
Number of subjects: 20
Study 11157569 — intervention group
Group type: COMPARATOR
Intervention: 1H‐MRSI in control subjects
Number of subjects: 20
Study 11157569 — intervention group
Group type: EXPERIMENTAL
Intervention: 1H‐MRSI in perilesional tissue
Number of subjects: 20
Study 11157569 — intervention group
Group type: EXPERIMENTAL
Intervention: 1H‐MRSI in contralateral tissue
Number of subjects: 20
Study 9042703 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirator wear condition
Number of subjects: 9
Study 9042703 — intervention group
Group type: COMPARATOR
Intervention: Control condition (without respirator)
Number of subjects: 9
Study 7937232 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent bradycardia pacemakers
Number of subjects: 588
Study 7937232 — intervention group
Group type: COMPARATOR
Intervention: Nonpacemaker patients
Number of subjects: 588
Study 2895910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 172
Study 2895910 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes (Control)
Number of subjects: 172
Study 31820841 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake per actual body weight (BW) categorized into quartiles (Q)
Number of subjects: 756
Study 31820841 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake per standard or target BW
Number of subjects: 756
Study 31820841 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for young-old population
Number of subjects: 756
Study 31820841 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for old-old population
Number of subjects: 756
Study 29214515 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a fundamentals of laparoscopic surgery (FLS™) standard box trainer
Number of subjects: 27
Study 29214515 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic computer based simulator (da Vinci Skills Simulator™)
Number of subjects: 27
Study 29214515 — intervention group
Group type: COMPARATOR
Intervention: No simulator training
Number of subjects: 27
Study 27062954 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial inhibitory technique (IT)
Number of subjects: 80
Study 27062954 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory technique (AT)
Number of subjects: 80
Study 27062954 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined technique (IT and AT)
Number of subjects: 80
Study 27062954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 80
Study 25615001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-directed telephone intervention with up to 3 attempts to reach each patient.
Number of subjects: 290
Study 25615001 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard pharmacy outreach (2 automated and 1 live call).
Number of subjects: 290
Study 23870189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg and propofol 1-2.5 mg/kg
Number of subjects: 60
Study 23870189 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% and propofol 1-2.5 mg/kg
Number of subjects: 60
Study 20929120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuichan Zhunsheng Decoction (CZD)
Number of subjects: 90
Study 20929120 — intervention group
Group type: COMPARATOR
Intervention: Pitocin (control)
Number of subjects: 90
Study 20929120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulator of CZD)
Number of subjects: 90
Study 18979718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination perindopril-indapamide
Number of subjects: 11140
Study 18979718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study 16802852 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (single intravenous 10-minute infusion at different dose levels ranging from 0.25 to 10 mg)
Number of subjects: 126
Study 16802852 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS
Number of subjects: 126
Study 12966321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.3 g/kg for men, 0.2 g/kg for women)
Number of subjects: 37
Study 12966321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 12966321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 37
Study 10983623 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-synchronized nebulization with mouthpiece
Number of subjects: 158
Study 10983623 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant output nebulization with mouthpiece
Number of subjects: 158
Study 10983623 — intervention group
Group type: COMPARATOR
Intervention: Nonsealing face mask with constant output nebulization
Number of subjects: 158
Study 8638838 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block with 7 ml 1% mepivacaine (n = 10)
Number of subjects: 20
Study 8638838 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 7 ml saline (n = 5)
Number of subjects: 20
Study 8638838 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection with 7 ml mepivacaine into the left deltoid muscle (n = 5)
Number of subjects: 20
Study 8638838 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study 1282218 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic substance P (SP) at doses of 0.5, 1, or 1.5 pmol/kg‐1/min‐1 over 60 min
Number of subjects: 7
Study 1282218 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic substance P (SP) at 1.5 pmol/kg‐1/min‐1 after pretreatment with sodium valproate (200 mg 16, 8 and 1 h before the SP test)
Number of subjects: 7
Study 1282218 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 7
Study 1282218 — intervention group
Group type: COMPARATOR
Intervention: Synthetic substance P (SP) at the lowest dose (0.5 pmol/kg‐1/min‐1)
Number of subjects: 7
Study 31326440 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular package viewing
Number of subjects: 34
Study 31326440 — intervention group
Group type: COMPARATOR
Intervention: Healthier package viewing
Number of subjects: 34
Study 31326440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasting healthier product
Number of subjects: 34
Study 31326440 — intervention group
Group type: COMPARATOR
Intervention: Tasting regular product
Number of subjects: 34
Study 28506776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi or physical therapy exercise (12 weeks, twice per week)
Number of subjects: 86
Study 25711628 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair with ETAC (n = 44)
Number of subjects: 88